One year after its Phase III failure in non-alcoholic steatohepatitis (NASH) with elafibranor, Genfit SA outlined its new R&D focus for investors on 11 May, headlined by a strategy to test a now-generic anti-infective drug in acute on chronic liver failure (ACLF). The French firm’s focus also remains on a pivotal Phase III study of elafibranor in second-line primary biliary cholangitis (PBC), as well as plans to test the drug and a second internally discovered PPAR agonist in first-line PBC as well as primary sclerosing cholangitis (PSC).
Genfit’s Post-NASH Plans Center On ACLF, Cholestatic Liver Disease
After last year’s Phase III failure in NASH, Genfit sees big opportunity in acute on chronic liver failure (ACLF), potentially with antiviral NTX. Its ongoing Phase III program in PBC as also is a potential revenue-driver.
More from Strategy
More from Business
• By
The US FDA approved anti-CD19 antibody Uplizna, from Amgen’s $27.8bn purchase of Horizon in 2023, for IgG4-related disease – a larger market than its original NMOSD indication.
• By
BeiGene’s Phase III ociperlimab joins the list of failed TIGIT inhibitors, as candidates from Roche, Merck & Co. and others have failed late-stage studies.
• By
It might be the beginning of the end for the orphan drugs party but there is still sales growth enjoyment to be had for the sector, whose star performers are now looking increasingly like mainstream drugs.